In this issue of JEM, Hulsmans et al. demonstrate that cardiac-resident MHC II high macrophages have a pathogenic role in heart failure with preserved ejection fraction (HFpEF) through their IL-10 production. The profi brotic eff ect of IL-10 autocrine loop promotes macrophages to secret osteopontin (OPN) and TGFβ. These mediators activate cardiac fi broblasts to produce collagen that results in cardiac fi brosis and increased cardiac stiff ness.
An estimated 8.5 million Americans will have heart failure (HF) by 2030, and nearly half of them will have HFpEF (Borlaug, 2014) . The impaired cardiac performance in HFpEF is a consequence of an increased left ventricular fi lling pressure caused by diastolic dysfunction. HFpEF is a life-threatening clinical problem with a paucity of therapies. General infl ammatory markers are increased in HFpEF, indicating the presence of systemic infl ammation. It has been shown before that the number of cardiac macrophages increases after a cardiac injury, such as myocardial infarction or myocarditis. In addition, myeloid cells play a pathogenic role in cardiac remodeling and heart failure (Baldeviano et al., 2010; Heidt et al., 2014) . Hulsmans et al. (2018) is the fi rst study to examine how cardiac macrophages contribute to the pathogenesis of HFpEF. Hulsmans et al. (2018) examined two murine models of HFpEF, as well as people with the disease. The fi rst model induces hypertension by combining salty drinking water, unilateral nephrectomy, and chronic exposure to aldosterone (SAU NA). The majority of patients with HFpEF have hypertension (Valero-Muñoz et al., 2016) . The second model utilizes physiologically aged mice with impaired diastolic function.
A majority of people with HFpEF are more than 60 yr old, and the pathology of HFpEF resembles changes that appear during normal cardiac aging (Borlaug, 2014) . Hulsmans et al. (2018) found that the number of macrophages in the heart increased in both models and in hearts of people with HFpEF. This increase in the number of cardiac macrophages was accompanied by an increase in myelopoiesis and in the number of blood monocytes migrating through CCR2 to the heart with HFpEF. The authors observed that cardiac macrophages are predominantly MHC II high and have increased IL-10 production compared with macrophages in a healthy heart. IL-10 is a cytokine produced by many leukocytes and stroma cells. It is important because of its antiinfl ammatory activity but also has profi brotic potential. Specifi c deletion of IL-10 from macrophages and monocytes using CX3CR1 Cre crossed to IL-10 fl oxed mice resulted in improvement of diastolic function with reduced left ventricular end-diastolic pressure and improved diastolic relaxation. IL-10 was deleted from all monocytes/macrophages because there is no specifi c cardiac macrophage marker that could be used for a targeted deletion. An interesting twist is that IL-10 does not directly act on cardiac fi broblasts, which lack the needed receptors, but has an autocrine eff ect on cardiac macrophages and induced their profi brotic phenotype. The IL-10-induced profi brotic macrophages activate the proliferation of myofi broblasts and production of collagen, which then leads to fi brosis-mediated cardiac stiff ness. One of the mediators in this interaction between macrophages and fi broblasts was identifi ed as OPN. The production of OPN was induced by IL-10 in macrophages by an autocrine manner (see fi gure, part A). The IL-10 induction of OPN as paracrine activator of cardiac fi broblasts was confi rmed by in vitro co-culture of fi broblasts and macrophages. Similarly, macrophage-derived TGFβ can also activate cardiac fi broblast. IL-10-defi cient SAU NA mice had an increased proportion of MHC II low macrophages in their hearts. MHC II low macrophages had higher protease and metalloproteinase (MMP) activity, as well as decreased expression of OPN and TGFβ (see fi gure, part B). The IL-10 pathogenic eff ect in HFpEF is especially interesting in light of a report of IL-10 antiinfl ammatory action on macrophages in various organs such as intestines (Ip et al., 2017) .
Healthy adult heart contains mostly embryonically derived macrophages and a smaller pool of macrophages replenished from blood monocytes (Epelman et al., 2014) . Cardiac-resident macrophages expand by in situ proliferation and by recruitment of blood monocytes in homeostasis; however, after injury, the uptake of monocytes from blood is the main mechanism of increasing the number of macrophages in the heart (Leuschner et al., 2012) . Cardiac-resident macrophages are remarkably diverse. They are defi ned as CD45 + cells expressing CD11b and F4/80 and CD64. Epelman et al. (2014) showed that four types of macrophages can be found in the healthy heart based on expression of CCR2, MHC II, and Ly6C. These categories replaced previously used M1/ M2 phenotypes because cardiac-resident macrophages are exposed to many diff erent stimuli in a complex tissue environment and therefore do not fi t well the in vitro defi ned M1/M2 phenotypes. Hulsmans et al. (2018) − is an equivalent to Ly6C low monocytes. After a cardiac injury, infl ammatory mediators act on the periphery, and increase monocytopoiesis in the bone marrow and spleen. Hulsmans et al. (2018) have also shown this mechanism in mouse models of HFpEF. Chemokines such as CCL2 are produced locally in the heart, mostly by cardiac fi broblasts after a cardiac injury and attract monocytes to the injured heart (Wu et al., 2014) . Ly6C high monocytes diff erentiate to macrophages in the heart. Together with the resident macrophages, their profi le is aff ected by an interaction with cardiac-resident cells, mainly cardiac fi broblasts. Cardiac fi broblasts can produce large amounts of granulocyte-macrophage colony-stimulating factor (GM-CSF) that determine the severity of cardiac remodeling and fi brosis in models of myocarditis, myocardial infarction, and Kawasaki disease by changing the profi le of myeloid cells in the heart (see fi gure, part C; Wu et al., 2014; Stock et al., 2016; Anzai et al., 2017) . Interestingly, cardiac fi broblasts can also produce CCL11 (eotaxin), which attracts eosinophils to the heart in the Th2 type of cardiac pathology in eosinophilic myocarditis (see fi gure, part C; Diny et al., 2016) . Hulsmans et al. (2018) also showed that IL-10 is produced not only by macrophages but also by cardiac fi broblasts, suggesting fi broblast contribution to IL-10 conditioning of macrophages. At the same time, cardiac fi broblasts are a target of myeloid cellderived infl ammatory mediators that lead to activation of fi broblasts, induce production of collagen, fi brosis, and cardiac remodeling. Hulsmans et al. (2018) identifi ed OPN and TGFβ as the mediators produced by macrophages and promoting collagen expression by cardiac fi broblasts. MHC II high monocytes, which are the main source of OPN and TGFβ, are also a source of many other infl ammatory mediators. Further research is needed to defi ne the role of myeloid cells and cardiac fi broblast in heart failure.
There is no eff ective therapy for HFpEF. It is a clinical issue of high importance, given that the incidence of HFpEF in the United States has grown by ∼10% per decade, as the result of population aging, as well as the increased incidence of the main risk factors for HFpEF, such as hypertension, obesity, and metabolic syndrome (Owan et al., 2006) . The pathophysiology of HFpEF used to be exclusively linked with diastolic dysfunction. However, we know now that there are other pathophysiological changes in the heart function, such as systolic impairment and decreased chronotropic reserve. In addition, peripheral abnormalities aff ecting skeletal muscle, endothelium, and autonomic nervous system are part of HFpEF pathology. Therefore, it is likely that HFpEF has a range of pathways of development, and it will be needed to identify subgroups of patients with HFpEF for targeted therapies. However, it is essential that a large clinical study is done to follow up on this possible new pathogenic mechanism in HFpEF.
Based on earlier fi ndings that HFpEF subjects have more collagen and less MMP activity (Kasner et al., 2011) , we can speculate that if IL-10 produced by MHC II high macrophages is shown to be also increased in larger and more diverse populations of HFpEF, then biological therapies that would modify cardiac macrophage phenotype and target mostly the MHC II high subtype might decrease interstitial fi brosis and cardiac stiffness, thereby addressing some symptoms of HFpEF. However, even MHC II high macrophages with their infl ammatory and profi brotic phenotype have important functions in the heart, especially in an acute response to injury after myocardial infarction and during myocarditis. Systemic neutralization of IL-10 might be a safer and more realistic biological therapy. It could perhaps be followed by a myeloid-specifi c targeting of IL-10. Future research should also examine how changes in the profi le of cardiac-resident macrophages and cytokine production aff ect cardiomyocytes because the increased stiff ness observed in HFpEF is considered to also be caused by changes in cardiomyocytes.
